To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
To map publication growth, collaboration, knowledge structure, and thematic change in artificial intelligence (AI) research in primary health care (PHC) and general practice and assess whether attention has expanded from model development to validation, implementation evaluation, and governance.
Background:
PHC AI research covers risk stratification, screening, diagnostic support, clinical decision support, and workflow optimization. However, publication growth and changing hotspots do not directly indicate clinical implementation or practical value.
Methods:
Web of Science Core Collection was searched for AI- and PHC-related records published from 1 January 2015 to 19 October 2025. Of 1,481 records, 1,261 articles and review articles were screened using titles, abstracts, and author keywords, Python-developed term lexicons, weighted scoring, and manual adjudication. Records lacking a specific PHC application, focused on public or consumer health, or insufficiently relevant were excluded. The main sample included 1,123 papers for bibliometric, collaboration, thematic, citation, and bibliographic coupling analyses. A supplementary search identified 599 candidates to assess omissions due to terminological variation; 142 remained after 457 exclusions and were added to form a 1,265-paper sensitivity corpus used only for keyword-frequency, co-occurrence, and annual trend reruns. Annual output was assessed for 2015 to 2024; 2025 was retained as an incomplete-year observation but excluded from complete-year comparisons.
Findings:
Annual output rose from 6 papers in 2015 to 220 in 2024 and increased continuously after 2018. Sensitivity analyses confirmed a stable thematic structure centred on AI, machine learning, PHC, electronic health records, screening and diagnosis, with overall increases in standardized AI- and PHC-term frequencies. Bibliographic coupling identified multiple application settings and model-evaluation topics. Model validation became more common; implementation/workflow remained visible, governance/regulation emerged after 2018, and fairness/bias and explainability were more prominent from 2022 to 2024. These findings indicate broader research attention, but do not demonstrate routine AI use or improved clinical outcomes.
Consortia like the Clinical Pharmacogenetic Implementation Consortium (CPIC) and the Dutch Pharmacogenetic Working Group (DPWG) provide clinical guidelines but pharmacogenomics implementation depends on population prevalence of actionable genetic variants and response phenotypes. We analyzed the distribution of actionable genetic variants and clinical recommendations in 14,354 adult Qataris, focusing only genes with guidelines (CYP2C19, CYP2D6, CYP2B6 and CYP3A4). Haplotypes and diplotypes were generated from 490 alleles using whole genome data and metabolizer phenotypes were predicted based on current knowledge. Qatari population predicted to have actionable metabolizer phenotypes of CYP2C19, CYP2B6 and CYP2D6 impacting response to antidepressants were in the range of 1%–58% and for antipsychotics 0.1%–33% based on CYP3A4 and CYP2D6. Fine-grained analysis based on clinical guidelines also revealed that while the Qataris may need prescription of an alternate antidepressant not metabolized by CYP2C19, patients from other populations may just need altering the dosage of tricyclic antidepressants like amitriptyline. Further studies incorporating other factors such as diet, environment and cultural habits alongwith population-specific variants will help in the pharmacogenomics implementation in the Qatari population.
The Amsterdam Instrumental Activities of Daily Living Questionnaire (A-IADL-Q) is well validated and commonly used to assess difficulties in everyday functioning regarding dementia. To facilitate interpretation and clinical implementation across different European countries, we aim to provide normative data and a diagnostic cutoff for dementia.
Methods:
Cross-sectional data from Dutch Brain Research Registry (N = 1,064; mean (M) age = 62 ± 11 year; 69.5% female), European Medial Information Framework-Alzheimer’s Disease 90 + (N = 63; Mage = 92 ± 2 year; 52.4% female), and European Prevention of Alzheimer’s Dementia Longitudinal Cohort Study (N = 247; Mage = 63 ± 7 year; 72.1% female) were used. The generalized additive models for location, scale, and shape framework were used to obtain normative values (Z-scores). The beta distribution was applied, and combinations of age, sex, and educational attainment were modeled. The optimal cutoff for dementia was calculated using area under receiver operating curves (AUC-ROC) and Youden Index, using data from Amsterdam Dementia Cohort (N = 2,511, Mage = 64 ± 8 year, 44.4% female).
Results:
The best normative model accounted for a cubic-like decrease of IADL performance with age that was more pronounced in low compared to medium/high educational attainment. The cutoff for dementia was 1.85 standard deviation below the population mean (AUC = 0.97; 95% CI [0.97–0.98]).
Conclusion:
We provide regression-based norms for A-IADL-Q and a diagnostic cutoff for dementia, which help improve clinical assessment of IADL performance across European countries.
Explorations of workflow development within primary care allow us to understand initial steps in the pace of knowledge and practice acclimatization within clinics. This study describes use of practice facilitation as an implementation strategy to communicate shared project goals and monitor and support refinement of practice behavior. This study engaged eight health care organizations, including 55 primary care practices, ≈380 clinicians, and ≈620 nursing and support staff in a guideline implementation project regarding United States Preventive Services Task Force use of aspirin recommendations for primary prevention of cardiovascular events.
The development of intensity modulated radiotherapy (IMRT) has allowed the delivery of concave dose distributions. Planning studies have demonstrated the potential clinical benefit of IMRT in the treatment of the prostate and pelvic nodes in patients with advanced prostate cancer. As a consequence, IMRT was clinically implemented in the Royal Marsden NHS Trust in September 2000, using Elekta Sli series linear accelerators and NOMOS Corvus v3.0 planning system. As a relatively new treatment procedure in the United Kingdom, the clinical implementation involved developing appropriate quality assurance and verification procedures as well as training staff. This paper describes the practicalities of implementing IMRT into the routine workload of the radiotherapy department.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.